2.52
-0.06 (-2.33%)
-0.06 (-2.33%)
Upgrade to Real-Time
Regular Market
Volume | 62,988 |
|
|||||
News | - | ||||||
Day High | 2.6281 | Low High |
|||||
Day Low | 2.38 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
9 Meters Biopharma Inc | NMTR | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.56 | 2.38 | 2.6281 | 2.58 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
293 | 62,988 | $ 2.52 | $ 158,986 | - | 1.00 - 14.888 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
15:46:50 | 10 | $ 2.51 | USD |
9 Meters Biopharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 32.65M | 12.96M | 12.80M | $ - | $ - | -2.98 | -0.90 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | - | - | 44.10% |
9 Meters Biopharma News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NMTR Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.02 | 2.6281 | 2.00 | 2.41 | 110,269 | 0.50 | 24.75% |
1 Month | 2.19 | 2.7899 | 1.96 | 2.26 | 88,443 | 0.33 | 15.07% |
3 Months | 2.26 | 2.7899 | 1.00 | 1.88 | 122,251 | 0.26 | 11.5% |
6 Months | 5.466 | 6.56 | 1.00 | 4.47 | 787,451 | -2.95 | -53.9% |
1 Year | 13.34 | 14.888 | 1.00 | 6.82 | 1,790,501 | -10.82 | -81.11% |
3 Years | 10.28 | 45.20 | 1.00 | 20.09 | 3,485,339 | -7.76 | -75.49% |
5 Years | 10.28 | 45.20 | 1.00 | 20.09 | 3,485,339 | -7.76 | -75.49% |
9 Meters Biopharma Description
9 Meters Biopharma Inc is a clinical-stage biopharmaceutical company focused on rare and unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS), celiac disease, and three early-stage candidates for undisclosed rare diseases and/or unmet needs. Its products include NM-002, Larazotide, NM-003 and others. |